A Review of the Ongoing Research on Zika Virus Treatment
AbstractThe Zika fever is an arboviral disease resulting from the infection with Zika virus (ZIKV). The virus is transmitted to humans by the bite of Aedes mosquitos, mainly Aedes aegypti and Aedes albopictus. ZIKV has been detected for decades in African and Asian regions and, since 2007, has spread to other continents; among them, infections are most reported in the Americas. This can be explained by the presence of vectors in highly populated and tropical regions where people are susceptible to contamination. ZIKV has been considered by the World Health Organization a serious public health problem because of the increasing number of cases of congenital malformation and neurological disorders related to its infection, such as microcephaly, Guillain–Barré syndrome, meningoencephalitis, and myelitis. There is no vaccine or specific antiviral against ZIKV. The infection is best prevented by avoiding mosquito bite, and the treatment of infected patients is palliative. In this context, the search for efficient antivirals is necessary but remains challenging. Here, we aim to review the molecules that have been described to interfere with ZIKV life cycle and discuss their potential use in ZIKV therapy. View Full-Text
Share & Cite This Article
da Silva, S.; Oliveira Silva Martins, D.; Jardim, A.C. A Review of the Ongoing Research on Zika Virus Treatment. Viruses 2018, 10, 255.
da Silva S, Oliveira Silva Martins D, Jardim AC. A Review of the Ongoing Research on Zika Virus Treatment. Viruses. 2018; 10(5):255.Chicago/Turabian Style
da Silva, Suely; Oliveira Silva Martins, Daniel; Jardim, Ana C. 2018. "A Review of the Ongoing Research on Zika Virus Treatment." Viruses 10, no. 5: 255.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.